Gregory S. Blank
Gregory S. Blank is the director of late-stage purification at Genentech, Inc.
Articles
Purification Strategies to Process 5 g/L Titers of Monoclonal Antibodies
Benedicte Lebreton;Amber R. Cothran;Sandy Sargis;Melody Trexler-Schmidt;Binh Q. Thai;Brian Kelley;Gregory S. Blank;Stefanie Sze-Khoo
March 2nd 2009Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Latest Updated Articles
Published: September 11th 2024 | Updated: September 18th 2024
CPHI Pharma Award Finalists Announced for 2024
Published: March 27th 2024 | Updated: June 28th 2024
AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product
Published: October 28th 2024 | Updated: November 24th 2024
Discovery to Commercialization: The Right Partnerships are Key to Streamlined Drug Development
Published: November 15th 2024 | Updated: November 24th 2024
Solving Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion Particle to Determine CQAs
Published: October 28th 2024 | Updated: November 24th 2024
Cell-based phenotypic screening with Incucyte® Live-Cell Analysis Systems
Published: October 22nd 2024 | Updated: November 24th 2024
Optimizing cGMP Facility Design Space with a Hybrid Approach
